Patient baseline demographics and disease characteristics at baseline and week 52 (extended population)
| Variable | SB4/SB4 (n=126) | ETN/SB4 (n=119) |
| Age, years | 49.9 (12.05) | 52.1 (10.91) |
| Women, n (%) | 107 (84.9) | 100 (84.0) |
| White, n (%) | 126 (100.0) | 118 (99.2) |
| BMI, kg/m2 | 26.7 (5.80) | 26.1 (5.05) |
| Disease duration, years | 5.7 (3.94) | 5.8 (4.18) |
| Duration of MTX use, months | 46.0 (35.63) | 43.9 (39.81) |
| Weekly dose of MTX, mg | 16.9 (4.92) | 16.5 (4.91) |
| Swollen joint count (0–66) | ||
| Baseline | 14.4 (7.25) | 14.4 (7.74) |
| Week 52 | 2.9 (4.84) | 2.8 (4.30) |
| Tender joint count (0–68) | ||
| Baseline | 21.0 (9.96) | 21.4 (11.08) |
| Week 52 | 5.0 (7.11) | 5.6 (7.86) |
| Physician VAS (0–100) | ||
| Baseline | 62.4 (16.35) | 63.6 (15.25) |
| Week 52 | 16.8 (14.47) | 18.8 (15.27) |
| Patient VAS (0–100) | ||
| Baseline | 58.9 (19.75) | 61.5 (18.08) |
| Week 52 | 24.9 (20.97) | 26.8 (19.62) |
| Patient pain VAS (0–100) | ||
| Baseline | 59.0 (21.38) | 60.5 (20.22) |
| Week 52 | 25.8 (21.86) | 27.0 (21.32) |
| HAQ-DI (0–3) | ||
| Baseline | 1.38 (0.555) | 1.45 (0.597) |
| Week 52 | 0.68 (0.585) | 0.74 (0.651) |
| DAS28 | ||
| Baseline | 6.22 (0.908) | 6.26 (0.877) |
| Week 52 | 3.40 (1.179) | 3.49 (1.119) |
| SDAI | ||
| Baseline | 37.01 (12.037) | 37.65 (12.052) |
| Week 52 | 10.04 (8.589) | 10.38 (8.713) |
| CDAI | ||
| Baseline | 35.85 (11.586) | 36.45 (11.672) |
| Week 52 | 9.41 (8.249) | 10.01 (8.670) |
| CRP, mg/L | ||
| Baseline | 11.5 (15.71) | 12.0 (16.35) |
| Week 52 | 6.2 (15.84) | 3.8 (5.47) |
| ESR, mm/h | ||
| Baseline | 41.9 (23.26) | 41.7 (19.53) |
| Week 52 | 24.5 (18.63) | 22.2 (16.21) |
| Rheumatoid factor positive, n (%) | 99 (78.6) | 89 (74.8) |
Values represent mean (SD) unless otherwise specified.
BMI, body mass index; CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; DAS28, disease activity score based on a 28-joint count; ESR, erythrocyte sedimentation rate; ETN, reference etanercept; HAQ-DI, Health Assessment Questionnaire-Disability Index; MTX, methotrexate; SDAI, Simplified Disease Activity Index; VAS, visual analogue scale.